Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.34 |
| ▸ | TRPV3 | Q8NET8 | 3/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.33 |
| ▸ | GCGR | P47871 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14338941 | 0.91 | P2RX7 (0.32) | P2RX7TRPV3TRPV1 | |
| SCHEMBL595991 | 0.89 | GCGR (0.38) | METAP2MAPK14GCGR | |
| SCHEMBL595773 | 0.86 | P2RX7 (0.33) | P2RX7TRPV3TRPV1 | |
| SCHEMBL596467 | 0.86 | NR3C1 (0.33) | P2RX7SCN9ATRPV3TRPV1 | |
| SCHEMBL595233 | 0.84 | GPR6 (0.34) | P2RX7TRPV3TRPV1 | |
| SCHEMBL597454 | 0.82 | METAP2 (0.39) | METAP2P2RX7SCN9ASCN10ATRPV3 | |
| SCHEMBL596651 | 0.79 | TRPV3 (0.32) | TRPV3 | |
| SCHEMBL596275 | 0.78 | METAP2 (0.36) | METAP2MAPK14GCGR | |
| SCHEMBL14338966 | 0.78 | P2RX7 (0.31) | P2RX7 | |
| SCHEMBL597115 | 0.76 | PSEN1 (0.40) | METAP2GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114886-B2 | Pyridylmethylsulfone derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-02-14 | — | — | US | disclosed |
| US-8114886-B2 | Pyridylmethylsulfone derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-02-14 | — | — | US | disclosed |
| US-8114886-B2 | Pyridylmethylsulfone derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20090149439-A1 | PYRIDYLMETHYSULFONE DERIVATIVE | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-06-11 | — | — | US | disclosed |
| US-20090149439-A1 | PYRIDYLMETHYSULFONE DERIVATIVE | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-06-11 | — | — | US | disclosed |
| EP-1867636-A1 | PYRIDYLMETHYLSULFONE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2007-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149439-A1 | PYRIDYLMETHYSULFONE DERIVATIVE | APP, IAPP, BACE1 | METAP2 205/4885P2RX7 2484/4885SCN9A 1029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.